Gapping up
In reaction to strong earnings/guidance:
- PING +18.8%, TGP +10%, PRSP +8%, HI +7.8%, DDS +7.7%, CPA +6.9%, IGT +4.7%, TNK +4%, WMT +3.1%, CHNG +2.4%, CBPO +2.2%, BAM +2.2%, VIAB +1.1%, PUMP +0.8%, NICE +0.7%
M&A news:
- QGEN +3.2% (after seeing late move higher on speculation of Thermo Fisher [TMO] interest in Qiagen)
Other news:
- XCUR +19.9% (Exicure & Allergan (AGN) enter global collaboration agreement -- Exicure will receive upfront payment of $25 mln)
- AVXL +6.7% (received the RPD designation from the FDA for ANAVEX2-73 (blarcamesine) for the treatment of Rett syndrome)
- AXNX +5% (announces FDA approval for its sacral neuromodulation system for urinary clinical indications)
- REPL +4.2% (prices public offering of 3,678,031 shares of its common stock at a public offering price of $13.61 per share)
- RETA +2.7% (upsizes offering by 400K shares and prices 2.4 mln shares of common stock at $183.00 per share)
- AZN +1.7% (US FDA accepts regulatory submission for selumetinib in neurofibromatosis type 1 and grants Priority Review)
- TPB +1.1% (promotes Graham A. Purdy to COO)
- SMPL +1% (CEO disclosed the purchase of ~16K shares worth ~$400K)
- AOBC +0.7% (announces intention to separate into two independent publicly traded companies)
- ATHX +0.7% (Healios receives notification of orphan designation for acute respiratory distress syndrome clinical program)
- LNT +0.7% (to make a public offering of $195.6 mln of shares of its common stock)
Analyst comments:
- FVRR +3% (upgraded to Buy from Neutral at BofA/Merrill)
- GLYC +2.2% (initiated with a Buy at ROTH Capital)
- SAH +1.9% (upgraded to Equal-Weight from Underweight at Morgan Stanley)
- BYND +1.4% (initiated with a Buy at Berenberg)
- ALSN +0.9% (upgraded to Buy from Neutral at BofA/Merrill)
- PCAR +0.9% (upgraded to Buy from Neutral at BofA/Merrill)